Kisspeptin-54 Research Guide

Overview

Longer-lasting version of Kisspeptin-10.

Usually given as a single shot to trigger ovulation during IVF.

What It Does

Full-length 54-amino acid kisspeptin, the endogenous master HPG axis regulator.

Binds KISS1R/GPR54 on GnRH neurons in hypothalamic arcuate nucleus and AVPV to trigger pulsatile GnRH release → LH/FSH → testosterone.

Reconstitution

Vial Size	BAC Water / Solvent	Concentration
5 mg	+ 1 mL	5 mg/mL

Interactive tool

Reconstitution Calculator

Enter the vial amount and diluent volume to calculate concentration. If you already have a target amount, you can also convert it to liquid volume and syringe markings. This tool does not recommend a target amount.

Vial amount

Diluent volume

Calculated concentration—Enter both values above.

Optional conversion

Enter a target amount you already have and select the syringe capacity.

Target amount

Syringe capacity

Calculated draw—Enter concentration inputs and a target amount.

Mathematical reference only. The calculator does not determine an appropriate target amount. Syringe capacity only changes the maximum volume that fits.

Protocol

Phase	Frequency	Amount	Notes
IVF trigger	Single dose	6.4 nmol/kg	Clinical IVF protocol. Oocyte maturation trigger vs hCG.
HPG restoration	3× weekly	100–300 mcg	Community HPG axis stimulation. Lower desensitisation risk than K-10 due to longer natural pulse.
Off	Cycle-dependent	–	No standard off period, use pulsatile protocol only.

Cycle & Timing

Pulsatile 3× weekly only. Daily dosing causes GPR54 desensitisation.

Timing

IVF trigger single shot or weekly.

Population Considerations

The LH/FSH response is hugely cycle-dependent, far stronger just before ovulation. Timing is everything. Men: Raises LH and testosterone, investigational for low-T and low lib The LH/FSH response is hugely cycle-dependent, far stronger just before ovulation. Timing is everything. Men: Raises LH and testosterone, investigational for low-T and low libido.

Handling & Stacking

Injection site

SubQ abdomen. IV for IVF protocols (clinical setting only).

Storage

Freeze-dried: -4°F.
Reconstituted: 36–46°F.
Best used within ~2–3 weeks (structure-based estimate, no published data); potency fades before the 28-day sterility limit, so keep it cold and dark and use it sooner.

Side effects

Facial flushing, warmth, mild abdominal discomfort (most common). Transient dizziness with IV administration. Generally very well tolerated.

What to expect

LH surge within 30–60 min of injection.
Testosterone rise within 2–4 hours.
Sustained HPG activation over 3× weekly protocol builds over 4–6 weeks.
Used as IVF trigger: oocyte maturation within 36–38 hrs at clinical dose.
Supply math 5mg → 1 vial (4-wk @ 300 mcg × 3/wk)

Pairs well with

HCG (additive HPG stimulation); CJC-1295 No DAC + Ipamorelin (anabolic environment); BPC-157 / TB-500 (recovery during cycle); PT-141 (sexual response synergy)

Avoid

Used too frequently, GPR54 desensitisation. Hormone-sensitive cancers. Pregnancy

Approved drug

Approved fertility options: clomiphene, hCG, injectable gonadotropins (FSH/hMG).

Safety & Patient Education

Contraindications

Hormone-sensitive malignancy (prostate cancer outside intentional ADT, breast cancer, ovarian cancer) Active thromboembolic disease Untreated thrombophilia Pregnancy (except specific fertility indications under specialist supervision) Polycythemia vera

Warnings

Estradiol elevation common; aromatase inhibitor may be needed Thromboembolic risk with elevated estradiol Ovarian hyperstimulation syndrome (OHSS) in females on HCG: can be life-threatening Mood changes, gynecomastia in males HCG raises both T and E2; estradiol monitoring is mandatory Longer half-life than K-10; lower desensitization risk but same axis effects

Drug interactions

AIs (anastrozole, letrozole): co-administered to manage E2; over-suppression worsens lipids and bone SERMs (clomiphene, tamoxifen): redundant overlap via central HPG drive Exogenous testosterone: shuts down LH/FSH, HCG efficacy reduced unless TRT paused or microdosed Anticoagulants (warfarin, DOACs): elevated E2 raises thromboembolic risk; coordinate if chronic Insulin / antidiabetics: HCG may shift glucose at high doses, monitor diabetic patients

Labs

Total & free testosterone, LH, FSH, sensitive E2; baseline, mid-cycle, end (LH/FSH Day 0/10/30) SHBG and prolactin at baseline CBC + hematocrit (polycythemia surveillance) Lipid panel; PSA in men >40 at baseline Semen analysis baseline + quarterly for fertility protocols D-dimer if clotting symptoms Out of range?
Low testosterone or high estradiol = the hormone axis needs tuning; hematocrit >54% = blood too thick (donate or hold).

Stop criteria

Hematocrit >54%, donate blood or hold therapy Estradiol persistently above target despite AI OHSS symptoms (abdominal distension, weight gain, dyspnea) Thrombosis symptoms (calf swelling, chest pain, dyspnea, neuro) New breast tenderness or growth (gynecomastia workup)

Patient education

Watch for clotting symptoms: leg swelling, calf pain, chest pain, sudden shortness of breath Estrogen side effects (gynecomastia, mood) manageable with AI under physician guidance Fertility protocols: 70+ days before semen analysis changes

References

peptidedosages · PubMed · thepeptidereport · Abbara 2015